Anna Brugulat-Serrat,Gonzalo Sánchez-Benavides,Raffaele Cacciaglia,Gemma Salvadó,Mahnaz Shekari,Lyduine E Collij,Christopher Buckley,Bart N M van Berckel,Andrés Perissinotti,Aida Niñerola-Baizán,Marta Milà-Alomà,Natàlia Vilor-Tejedor,Grégory Operto,Carles Falcon,Oriol Grau-Rivera,Eider M Arenaza-Urquijo,Carolina Minguillón,Karine Fauria,José Luis Molinuevo,Marc Suárez-Calvet,Juan Domingo Gispert,ALFA Study,Alba Cañas,Lidia Canals,Laura Iglesias,Paula Marne,Annabella Beteta,Carme Deulofeu,Maria Emilio,Irene Cumplido,Ruth Domínguez,Sherezade Fuentes,Laura Hernández,Marc Vilanova,Lluís Solsona,Gema Huesa,Jordi Huguet,Tania Menchón,Albina Polo,Sandra Pradas,Aleix Sala-Vila,Anna Soteras,Laura Stankeviciute,Müge Akinci,Eleni Palpatzis,Patricia Genius,Blanca Rodríguez,Marina García,Paula Ortiz-Romero

Abstract:Purpose: To determine whether the APOE-ε4 allele modulates the relationship between regional β-amyloid (Aβ) accumulation and cognitive change in middle-aged cognitively unimpaired (CU) participants. Methods: The 352 CU participants (mean aged 61.1 [4.7] years) included completed two cognitive assessments (average interval 3.34 years), underwent [18F]flutemetamol Aβ positron emission tomography (PET), T1w magnetic resonance imaging (MRI), as well as APOE genotyping. Global and regional Aβ PET positivity was assessed across five regions-of-interest by visual reading (VR) and regional Centiloids. Linear regression models were developed to examine the interaction between regional and global Aβ PET positivity and APOE-ε4 status on longitudinal cognitive change assessed with the Preclinical Alzheimer's Cognitive Composite (PACC), episodic memory, and executive function, after controlling for age, sex, education, cognitive baseline scores, and hippocampal volume. Results: In total, 57 participants (16.2%) were VR+ of whom 41 (71.9%) were APOE-ε4 carriers. No significant APOE-ε4*global Aβ PET interactions were associated with cognitive change for any cognitive test. However, APOE-ε4 carriers who were VR+ in temporal areas (n = 19 [9.81%], p = 0.04) and in the striatum (n = 8 [4.14%], p = 0.01) exhibited a higher decline in the PACC. The temporal areas findings were replicated when regional PET positivity was determined with Centiloid values. Regionally, VR+ in the striatum was associated with higher memory decline. As for executive function, interactions between APOE-ε4 and regional VR+ were found in temporal and parietal regions, and in the striatum. Conclusion: CU APOE-ε4 carriers with a positive Aβ PET VR in regions known to accumulate amyloid at later stages of the Alzheimer's disease (AD) continuum exhibited a steeper cognitive decline. This work supports the contention that regional VR of Aβ PET might convey prognostic information about future cognitive decline in individuals at higher risk of developing AD. Clinicaltrials: gov Identifier: NCT02485730. Registered 20 June 2015 https://clinicaltrials.gov/ct2/show/NCT02485730 and ClinicalTrials.gov Identifier:NCT02685969. Registered 19 February 2016 https://clinicaltrials.gov/ct2/show/NCT02685969 .

APOE3 Christchurch Heterozygosity and Autosomal Dominant Alzheimer's Disease

APOE3 Christchurch modulates β-catenin/Wnt signaling in iPS cell-derived cerebral organoids from Alzheimer's cases

Impact of APOE ε4 and ε2 on plasma neurofilament light chain and cognition in autosomal dominant Alzheimer's disease

APOE3ch Alleviates Aβ and Tau Pathology and Neurodegeneration in the Human APPNL-G-F Cerebral Organoid Model of Alzheimer’s Disease

Protection against Alzheimer's Disease with APOE Christchurch Variant — How?

APOE-ε4 modulates the association between regional amyloid deposition and cognitive performance in cognitively unimpaired middle-aged individuals

Resilience to autosomal dominant Alzheimer's disease in a Reelin-COLBOS heterozygous man

Multiomics integrative analysis identifies APOE allele-specific blood biomarkers associated to Alzheimer’s disease etiopathogenesis

Associations Between APOE Genotype and Cerebral Small-Vessel Disease: a Longitudinal Study

APOE Christchurch enhances a disease-associated microglial response to plaque but suppresses response to tau pathology

Single-nucleus RNA sequencing demonstrates an autosomal dominant Alzheimer's disease profile and possible mechanisms of disease protection

Single-nucleus RNA sequencing demonstrates an autosomal dominant Alzheimer’s disease profile and possible mechanisms of disease protection

The APOE-R136S mutation protects against APOE4-driven Tau pathology, neurodegeneration and neuroinflammation

Effect of apolipoprotein genotype and educational attainment on cognitive function in autosomal dominant Alzheimer's disease

Potential Modifying Effect of the APOEε4 Allele on Age of Onset and Clinical Manifestations in Patients with Early-Onset Alzheimer's Disease with and without a Pathogenic Variant in PSEN1 in a Sample of the Mexican Population

Generation of three isogenic, gene-edited iPSC lines carrying the APOE-Christchurch mutation into the three common APOE variants: APOE2Ch , APOE3Ch and APOE4Ch

Identification of a specific APOE transcript and functional elements associated with Alzheimer's disease

APOE loss-of-function variants: Compatible with longevity and associated with resistance to Alzheimer's Disease pathology

Deciphering ApoE Genotype-Driven Proteomic and Lipidomic Alterations in Alzheimer’s Disease Across Distinct Brain Regions

The Specific Impact of Apolipoprotein E Epsilon 2 on Cognition and Brain Function in Cognitively Normal Elders and Mild Cognitive Impairment Patients

Differences in Grey Matter Concentrations and Functional Connectivity between Young Carriers and Non-Carriers of the APOE ε4 Genotype